Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma
Author:
Affiliation:
1. Department of Lymphoma and Myeloma,
2. Department of Stem Cell Transplantation and Cellular Therapy,
3. Division of Pharmacy, and
4. Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
Publisher
American Society of Hematology
Subject
Hematology
Link
http://ashpublications.org/bloodadvances/article-pdf/4/13/3123/1748264/advancesadv2020002328.pdf
Reference14 articles.
1. Hitting a moving target: successful management of diffuse large B-cell lymphoma involving the mesentery with volumetric image-guided intensity modulated radiation therapy;Yoder;Clin Lymphoma Myeloma Leuk,2019
2. Self-reported incident hypertension and long-term kidney function in living kidney donors compared with healthy nondonors;Holscher;Clin J Am Soc Nephrol,2019
3. Locke FL , RossiJ, XueX, et al Immune signatures of cytokine release syndrome and neurologic events in a multicenter registrational trial (ZUMA-1) in subjects with refractory diffuse large B cell lymphoma treated with axicabtagene ciloleucel (KTE-C19) [abstract]. Cancer Res. 2017;77(suppl 13). Abstract CT020.
4. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells;Norelli;Nat Med,2018
5. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade;Giavridis;Nat Med,2018
Cited by 140 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting cytokine networks in neuroinflammatory diseases;Nature Reviews Drug Discovery;2024-09-11
2. Need for standardization of cytokine profiling in CAR T cell therapy;Molecular Therapy;2024-09
3. CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations;Blood Advances;2024-08-16
4. Late-onset relapsing neurotoxicity after Brexucabtagene autoleucel associated with high chimeric antigen receptor T cells in cerebrospinal fluid;Cytotherapy;2024-08
5. Novel Treatment Modality for Chimeric Antigen Receptor T-cell Therapy Complications: A Case Report;Cureus;2024-07-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3